Search results for " infectious disease"

showing 10 items of 167 documents

Essential strategies in HAI prevention and control: performance assessment through the implementation of the HAI-CoSIP tool of the GISIO-SItI group. …

2018

Healthcare-Associated Infections are a great concern for worldwide healthcare systems and represent a considerable threat to patient safety, leading to adverse clinical outcomes. A defined panel of indicators represents a key element to guide Healthcare Organizations towards identification of main gaps, implementation of effective actions and continuous improvements on Healthcare-Associated Infections prevention and control activities. A review on accreditation systems conducted by the Italian Study Group of Hospital Hygiene of the Italian Society of Hygiene Preventive Medicine and Public Health revealed a substantial heterogeneity of implemented standards and led to the development of a co…

Cross InfectionHealthcare-Associated Infections (HAIs); Institutional accreditation; Performance assessment; Quality improvement;Environmental and Occupational HealthPilot ProjectsAccreditationInstitutional accreditationPerformance assessmentCross-Sectional StudiesInfectious DiseasesItalyHealthcare-Associated Infections (HAIs); Institutional accreditation; Performance assessment; Quality improvement; Public Health Environmental and Occupational Health; Infectious DiseasesCatheter-Related InfectionsFeasibility StudiesHumansSurgical Wound InfectionHealthcare-Associated Infections (HAIs); Institutional accreditation; Performance assessment; Quality improvementPublic HealthQuality improvementDelivery of Health CareHealthcare-Associated Infections (HAIs)
researchProduct

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

2018

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter def…

CyclopropanesLiver CirrhosisMaleCirrhosis;Dasabuvir;Elderly;Ombitasvir;ParitaprevirCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged; 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy; Combination; GenotypeParitaprevirCirrhosis Dasabuvir Elderly Ombitasvir Paritaprevir Microbiology (medical) Infectious DiseasesCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; Genotype; Microbiology (medical); Infectious DiseasesHepacivirusGastroenterologychemistry.chemical_compound0302 clinical medicineElderly2-Naphthylamine80 and overMedicineAnilides030212 general & internal medicineChronicAged 80 and overSulfonamidesDasabuvirValineGeneral MedicineHepatitis CHepatitis CTreatment OutcomeInfectious DiseasesCirrhosisCombination030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleDasabuvirMacrocyclic CompoundCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Microbiology (medical); Infectious Diseasesmedicine.drugHumanMicrobiology (medical)medicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicSettore MED/12 - GASTROENTEROLOGIALiver CirrhosiSulfonamideAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinHumansDecompensationUracilAgedHepatitisAntiviral AgentCirrhosiHepaciviruRitonavirbusiness.industryRibavirinSettore MED/09 - MEDICINA INTERNAAnilideBiomarkerHepatitis C Chronicmedicine.diseaseCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; GenotypeOmbitasvirOmbitasvirchemistryParitaprevirCarbamateRitonavirCarbamatesbusinessBiomarkers
researchProduct

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A met…

2017

The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4. To confirm the effectiveness of this regimen in the real world, we conducted meta-analyses of published literature on 30 April 2016. Freeman-Tukey transformation determined the SVR rate within GTs 1a, 1b, and 4, as well as specific SVR rates by cirrhosis or prior treatment experience status. Rates of virologic relapse, hepatic decompensation, drug discontinuation, and serious adverse events were also …

CyclopropanesLiver CirrhosisSustained Virologic ResponseHCV genotypes 1 and 4ComorbidityHepacivirusmedicine.disease_causeGastroenterologymeta-analysichemistry.chemical_compound0302 clinical medicineAnilides030212 general & internal medicineSulfonamidesDasabuvirValineHepatitis CViral LoadHepatitis Creal-world effectiveneInfectious DiseasesTreatment Outcome2D; 3D; HCV genotypes 1 and 4; hepatitis C; meta-analysis; real-world effectiveness; Hepatology; Infectious Diseases; Virology030211 gastroenterology & hepatologyDrug Therapy Combinationmedicine.drug3Dmedicine.medical_specialtyMacrocyclic CompoundsGenotypeProlineHepatitis C virusLactams MacrocyclicInfectious DiseaseAntiviral Agents03 medical and health sciencesInternal medicineVirologyRibavirinmedicineHumans2DRitonavirHepatologybusiness.industryRibavirinmedicine.diseaseOmbitasvirRegimenchemistryParitaprevirImmunologyRitonavirCarbamatesbusinessJournal of viral hepatitis
researchProduct

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

2015

Objective: The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved. We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients. Design: Observational European cohort collaboration study. Methods: Eligible patients were antiretroviral-naive with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load ( 50 copies/ml) after initial s…

CyclopropanesMaleEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body WeightHIV InfectionsOverweight10234 Clinic for Infectious DiseasesCohort Studieschemistry.chemical_compoundAntiretroviral Therapy Highly ActiveImmunology and AllergyHIV InfectionImmunological responsevirus diseasesVirological responseMiddle AgedViral LoadReverse Transcriptase InhibitorTreatment OutcomeInfectious DiseasesAlkynesCohort2723 Immunology and AllergyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.symptomViral loadCohort studyHumanBenzoxazineAdultmedicine.medical_specialtyEfavirenzImmunologyAntiretroviral Therapy610 Medicine & healthRegression AnalysiPharmacokineticsInternal medicinemedicineHumansHighly ActiveObesity2403 Immunologybusiness.industryProportional hazards modelBody WeightHIV2725 Infectious DiseasesEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body Weight; Immunology and Allergy; Immunology; Infectious Diseasesmedicine.diseaseWeightObesityBenzoxazinesCD4 Lymphocyte Countlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]chemistryImmunologyCohort StudieEfavirenzbusiness
researchProduct

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir i…

2013

Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, define…

CyclopropanesTime FactorsPyridinesPyridineDrug ResistanceLopinavir/ritonavirLongitudinal StudieHIV InfectionsPharmacologyAntiviral therapyDeoxycytidineLopinavirCohort Studieschemistry.chemical_compoundimmune system diseasesRetrospective StudieOrganophosphonateMedicineEmtricitabineHIV InfectionPharmacology (medical)ViralLongitudinal StudiesProspective StudiesProspective cohort studyvirus diseasesLopinavirInfectious DiseasesAnti-Retroviral AgentsItalyAlkynesCombinationOligopeptideHIV/AIDSDrug Therapy CombinationOligopeptidesmedicine.drugHumanMicrobiology (medical)Benzoxazinemedicine.medical_specialtyEfavirenzTime Factorantiretroviral therapyAtazanavir SulfateOrganophosphonatesfirst-line therapy tenofovir emtricitabine atazanavir/ritonavirSettore MED/17 - MALATTIE INFETTIVEEmtricitabineDurabilityDrug TherapyInternal medicineDrug Resistance ViralDrug utilizationHumansAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Time Factors; Pharmacology; Pharmacology (medical); Infectious DiseasesTenofovirRetrospective StudiesAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time FactorsPharmacologyRitonavirbusiness.industryAdenineAtazanavirBenzoxazinesRegimenProspective StudiechemistryHIV-1RitonavirAnti-Retroviral AgentCohort StudieTenofovir/emtricitabinebusiness
researchProduct

Permeability changes of integrin-containing multivesicular structures triggered by picornavirus entry.

2014

Cellular uptake of clustered α2β1-integrin induces the formation of membrane compartments that subsequently mature into a multivesicular body (MVB). Enhanced internalization mediated by clustered integrins was observed upon infection by the picornavirus echovirus 1 (EVI). We elucidated the structural features of virus-induced MVBs (vMVBs) in comparison to antibody-induced control MVBs (mock infection) by means of high-pressure cryo fixation of cells followed by immuno electron tomography during early entry of the virus. Three-dimensional tomograms revealed a marked increase in the size and complexity of these vMVBs and the intraluminal vesicles (ILVs) at 2 and 3.5 hours post infection (p.i.…

CytoplasmElectron Microscope TomographyEchovirusPicornaviruslcsh:MedicinePicornaviridaemedicine.disease_causeBiochemistryCell membrane2.1 Biological and endogenous factors2.2 Factors relating to the physical environmentAetiologylcsh:ScienceInternalizationmedia_common0303 health sciencesMicroscopyMicroscopy ConfocalMultidisciplinaryTumorbiology030302 biochemistry & molecular biologyMultivesicular Bodies3. Good healthCell biologymedicine.anatomical_structureInfectious DiseasesConfocalIntegrin alpha2beta1InfectionResearch ArticleBiotechnologyEndosomeGeneral Science & Technologymedia_common.quotation_subjectBiophysicsEndosomesMicrobiologyPermeabilityCell Line03 medical and health sciencesCell Line TumormedicineHumansMultivesicular BodyMolecular Biology030304 developmental biologyPicornaviridae Infectionslcsh:RVirus Uncoatingta1183Cell Membraneta1182Biology and Life SciencesComputational BiologyCell Biologybiology.organism_classificationEmerging Infectious DiseasesCytoplasmlcsh:Q
researchProduct

A look into the future of the COVID-19 pandemic in Europe : an expert consultation

2021

How will the coronavirus disease 2019 (COVID-19) pandemic develop in the coming months and years? Based on an expert survey, we examine key aspects that are likely to influence COVID-19 in Europe. The future challenges and developments will strongly depend on the progress of national and global vaccination programs, the emergence and spread of variants of concern, and public responses to nonpharmaceutical interventions (NPIs). In the short term, many people are still unvaccinated, VOCs continue to emerge and spread, and mobility and population mixing is expected to increase over the summer. Therefore, policies that lift restrictions too much and too early risk another damaging wave. This ch…

Delphi methodPsychological intervention: Multidisciplinaire généralités & autres [F99] [Sciences du vivant]0302 clinical medicineCOVID-19 (Disease) -- Risk factors -- EuropePandemic030212 general & internal medicine: Multidisciplinary general & others [D99] [Human health sciences]0303 health sciencesEurope policy adviceHealth PolicyPublic Health Global Health Social Medicine and EpidemiologyOther Quantitative Biology (q-bio.OT)Quantitative Biology - Other Quantitative Biology3. Good healthCoronavirus infections -- EuropeVaccinationEuropegroup forecastOncologyCOVID-19 (Disease) -- Vaccination -- EuropePublic aspects of medicineRA1-1270: Immunology & infectious disease [D12] [Human health sciences]Coronavirus disease 2019 (COVID-19): Multidisciplinaire généralités & autres [D99] [Sciences de la santé humaine]610: Multidisciplinary general & others [F99] [Life sciences]variants of concernexpert survey03 medical and health sciencesViewpointSocial distancing (Public health) and education -- EuropeIntensive careDevelopment economicsInternal MedicineCOVID-19 (Disease) -- Europeddc:610non-pharmaceutical interventions030304 developmental biologypolicy adviceSARS-CoV-2Population mixingCOVID-19 Pandemic 2020- -- EuropeCOVID-19Expert consultationDelphi studyFolkhälsovetenskap global hälsa socialmedicin och epidemiologi: Immunologie & maladie infectieuse [D12] [Sciences de la santé humaine]FOS: Biological sciencesBusinessHuman medicine
researchProduct

Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor+ Regulatory T Cells

2012

SummaryMature dendritic cells (DCs) are established as unrivaled antigen-presenting cells (APCs) in the initiation of immune responses, whereas steady-state DCs induce peripheral T cell tolerance. Using various genetic approaches, we depleted CD11c+ DCs in mice and induced autoimmune CNS inflammation. Unexpectedly, mice lacking DCs developed aggravated disease compared to control mice. Furthermore, when we engineered DCs to present a CNS-associated autoantigen in an induced manner, we found robust tolerance that prevented disease, which coincided with an upregulation of the PD-1 receptor on antigen-specific T cells. Additionally, we showed that PD-1 was necessary for DC-mediated induction o…

Encephalomyelitis Autoimmune ExperimentalT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationCD11cAutoimmunity610 Medicine & healthchemical and pharmacologic phenomenaBiologymedicine.disease_causeAutoantigensT-Lymphocytes RegulatoryB7-H1 AntigenAutoimmunityImmune toleranceMiceImmune systemDownregulation and upregulationImmune TolerancemedicineAnimalsImmunology and AllergyReceptorMice KnockoutAntigen Presentation2403 Immunologyhemic and immune systemsDendritic Cells2725 Infectious DiseasesTh1 CellsCD11c AntigenMice Inbred C57BLInfectious Diseasesmedicine.anatomical_structure10032 Clinic for Oncology and HematologyImmunology2723 Immunology and AllergyTh17 CellsImmunity
researchProduct

Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey

2020

Purpose To survey healthcare workers (HCW) on availability and use of personal protective equipment (PPE) caring for COVID-19 patients in the intensive care unit (ICU). Materials and method A web-based survey distributed worldwide in April 2020. Results We received 2711 responses from 1797 (67%) physicians, 744 (27%) nurses, and 170 (6%) Allied HCW. For routine care, most (1557, 58%) reportedly used FFP2/N95 masks, waterproof long sleeve gowns (1623; 67%), and face shields/visors (1574; 62%). Powered Air-Purifying Respirators were used routinely and for intubation only by 184 (7%) and 254 (13%) respondents, respectively. Surgical masks were used for routine care by 289 (15%) and 47 (2%) for…

Face shieldMalebusiness.product_categoryHot TemperatureInfectious Disease TransmissionAllied Health PersonnelNursesCritical Care and Intensive Care MedicineOccupational safety and healthlaw.inventionPatient-to-Professional0302 clinical medicinelawSurveys and QuestionnairesPersonal protective equipmentHealth careMedicine and Health SciencesViralRespiratorRespiratory Protective DevicesHealth care workersHealth services researchHeadacheMasksMiddle AgedIntensive care unitEuropeIntensive Care UnitsFemaleSafetyCoronavirus InfectionsEye Protective DevicesThirstAdultmedicine.medical_specialtyCOVID-19; Health care workers; Intensive care; Personal protective equipment; Safety; Adult; Africa; Allied Health Personnel; Asia; Betacoronavirus; COVID-19; Coronavirus Infections; Europe; Eye Protective Devices; Female; Gloves Protective; Headache; Hot Temperature; Humans; Infectious Disease Transmission Patient-to-Professional; Intensive Care Units; Male; Masks; Middle Aged; North America; Nurses; Oceania; Pandemics; Personal Protective Equipment; Personnel Staffing and Scheduling; Physicians; Pneumonia Viral; Respiratory Protective Devices; SARS-CoV-2; South America; Surgical Attire; Surveys and Questionnaires; Thirst; Health Personnel; Occupational HealthInfectious Disease Transmission Patient-to-ProfessionalAsiaHealth PersonnelPneumonia ViralGlovesOceaniaPersonnel Staffing and SchedulingArticle03 medical and health sciencesBetacoronavirusIntensive carePhysiciansmedicineHumansSurgical AttirePersonal protective equipmentPandemicsOccupational Healthbusiness.industrySARS-CoV-2COVID-19030208 emergency & critical care medicinePneumoniaSouth AmericaProtective030228 respiratory systemCOVID-19Personal protective equipmentSafety Health care workersIntensive careIntensive careEmergency medicineAfricaNorth AmericabusinessGloves ProtectiveJournal of Critical Care
researchProduct

Promoting influenza prevention for elderly people in Hong Kong using health action process approach: study protocol.

2018

People 65 years or older are at greater risk of serious complications from the seasonal influenza compared with young. To promote elderly people’s behavioral compliance toward influenza prevention, the aim of the current project is to develop, implement, and evaluate a theory-based low-administration-cost intervention building on a leading psychological theory, the Health Action Process Approach (HAPA). The target group is Hong Kong Chinese elderly people aged 65 or older who rarely or never adopt any preventive actions. This project will be conducted in three phases over 24 months. In phase 1, intervention program will be developed building on the HAPA theoretical framework which comprises…

GerontologyAgingand promotion of well-beinglaw.inventionStudy Protocol0302 clinical medicineinfluenssaRandomized controlled trial7.1 Individual care needslawMedicine030212 general & internal medicinelcsh:Public aspects of medicineInfectious DiseasesOlder adultsPneumonia & InfluenzaPublic Health and Health ServicesHong KongPsychological theoryPublic Health0305 other medical scienceikääntyneetBehavior maintenanceHumanmedicine.medical_specialtyterveyspsykologiaClinical Trials and Supportive ActivitiesHealth Promotion03 medical and health sciencesClinical ResearchIntervention (counseling)Influenza HumanInfluenza preventionBehavioral and Social ScienceHumansAgedGovernment030505 public healthbusiness.industryHealth action process approachPublic healthPreventionPublic Health Environmental and Occupational Healthlcsh:RA1-1270Prevention of disease and conditionsInfluenzaTelephoneBehavior initiationClinical trialInfluenza preventionEmerging Infectious DiseasesGood Health and Well Beingterveyskäyttäytyminen3.1 Primary prevention interventions to modify behaviours or promote wellbeingBiostatisticsbusiness3.1 Primary prevention interventions to modify behaviours or promote well-beingProgram Evaluation
researchProduct